Halo Pharma Set to Launch New Sterile Injectable Manufacturing Capabilities at Whippany Facility
Halo Pharma Set to Launch New Sterile Injectable Manufacturing Capabilities at Whippany Facility $45 million investment delivers critical domestic sterile manufacturing capacity to pharmaceutical partners
Inside Halo’s New Fill-Finish Platform
Inside Halo’s New Fill-Finish Platform Glenn Herring took PharmTech inside our new sterile fill-finish manufacturing platform to show how we are expending capabilities and positioning
Three Formats, One Platform: Halo’s New Sterile Fill-Finish Line
Three Formats, One Platform: Halo’s New Sterile Fill-Finish Line Halo Pharma is building to close the gap in the U.S. injectable supply chain, and PharmTech
Halo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco
Halo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco Independent CDMO positioned for growth in sterile injectables and other complex drug product formats
Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals
Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals Weston, Florida and Whippany, New Jersey — April 14, 2026 – Apotex Corp. today announced
Parenteral and Sterile Fill-Finish Development and Manufacturing Trends
Halo Pharma Executive Chairman Lee Karras says escalating equipment and component costs are the two biggest challenges facing parenteral/sterile drug product manufacturers.
Halo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)
Whippany, NJ – January 27, 2026 SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to
Halo Pharma Enhances Manufacturing Capabilities with Macro-Pactor Investment
Whippany, NJ – December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor® to be online
Halo Pharma nomme Laurent Malgouyres directeur du site de Mirabel, au Canada.
Whippany, NJ – October 14, 2025 Malgouyres joins Halo with over 14 years of operational experience in the pharmaceutical industry As site director, he will
John Bender rejoint Woodstock Sterile Solutions, Halo Pharma, en tant que vice-président du développement commercial
Woodstock, IL, August 12, 2025 Bender brings 35 years of pharmaceutical industry experience to dual role Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development